• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aptahem

0.46 SEK

-7.06 %

Less than 1K followers

APTA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-7.06 %
-27.52 %
-32.21 %
-58.55 %
-58.55 %
-58.31 %
-97.27 %
-99.58 %
-99.91 %

Aptahem operates in the pharmaceutical industry. The company develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's lead candidate is being developed as an emergency drug intended to prevent the onset of life-threatening organ and tissue damage in patients suffering from sepsis. A large part of the research is carried out in collaboration with partners in the industry. The company was founded in 2014 and is headquartered in Malmö.

Read more
Market cap
11.96M SEK
Turnover
2.31K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
27.8
2026

Interim report Q2'26

Press release22.06.2026, 08.19

Aptahem: Newsletter June 2026

Aptahem
Press release17.06.2026, 08.30

Aptahem Improves Quality and Manufacturing Efficiency in a New Apta-1 Test Batch

Aptahem
Press release05.06.2026, 14.12

Aptahem to Participate at IOPC 2026 in Athens

Aptahem

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11.05.2026, 10.51

Aptahem: Newsletter May 2026

Aptahem
Press release19.12.2025, 16.00

Aptahem: Newsletter December 2025

Aptahem
Regulatory press release05.12.2025, 08.52

Aptahem receives patent protection in China for patent family 2

Aptahem
Press release30.10.2025, 09.56

Aptahem's webinar "Strategic Direction and Planned US Listing" now available

Aptahem
Press release22.10.2025, 12.49

Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing

Aptahem
Press release21.10.2025, 08.45

Aptahem: Newsletter October 2025

Aptahem
Press release25.09.2025, 15.19

Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue

Aptahem
Regulatory press release23.09.2025, 11.53

Aptahem receives Notice of Allowance in China for patent family 2

Aptahem
Press release19.09.2025, 08.44

Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation

Aptahem
Regulatory press release27.08.2025, 16.53

Aptahem is applying to the FDA's CNPV pilot program for accelerated drug review

Aptahem
Press release27.08.2025, 13.33

Aptahem: Newsletter No 2, August 2025

Aptahem
Regulatory press release26.08.2025, 09.21

Aptahem announces Strategic Direction for U.S. Listing to Enable Phase 2 Study and build portfolio assets value

Aptahem
Regulatory press release20.08.2025, 10.07

Aptahem files provisional patent application in USA for new indications for Apta-1

Aptahem
Regulatory press release13.08.2025, 14.13

Aptahem Applies to FDA PreCheck Program - Strategic Step Toward Faster, Higher-Quality Drug Manufacturing

Aptahem
Regulatory press release20.05.2025, 16.20

Aptahem receives strong interest in partnership from a European pharmaceutical company

Aptahem